Stay updated with breaking news from Revised Upper Limb Module. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months - These data indic
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that two-year data from the JEWELFISH study, which evaluated Evrysdi (risdiplam) ...
Investegate announcements from F. Hoffmann-La Roche Ltd, Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
- Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)- Actively enrolling in pivotal Phase 3 SAPPHIRE clinical trial for apitegromab- Discovery pipeline advancements made for LTBP-TGFβ1 target to tre...
Cognitive function was associated with disease severity and motor impairment in patients with type 3 SMA, suggesting the presence of intrinsic brain pathology.